Clal Biotechnology Industries (CBI)

Clal Biotechnology Industries is a publicly traded life sciences holding company in Tel Aviv that partners with multinational pharma to finance, develop, and commercialize treatments for unmet medical needs. The corporate VC structure and public listing mean its investment behavior reflects both venture economics and public-market disclosure pressures, which can be a useful discipline for founders willing to operate with quarterly transparency in mind.

Stages cover Seed through Growth, with check sizes between $5 million and $25 million. Sub-verticals listed are biotech and pharma. The record does not name specific portfolio companies, but the firm’s pharma partnership orientation suggests assets that can plug into existing pharma development pipelines rather than standalone software platforms.

Founders should approach CBI when the asset has a credible therapeutic angle and a partner-able profile. Pure healthcare AI software without a drug development or therapeutic asset hook will not fit. Pharma-aligned drug discovery platforms, novel modalities, and clinical-stage therapeutics are the natural matches. Founders should be ready to discuss out-licensing, strategic partnership terms, and milestone economics rather than purely venture growth metrics. Israeli incorporation or a strong Israeli operating base will help, and founders should expect rigorous scientific and regulatory diligence consistent with a public company that owns biotech assets.